Generic drugs play a significant role in India, where the majority of people can afford and rely on them because they are inexpensive and widely available. However, some pharmaceutical companies' licenses were revoked because unsold or banned products of branded drugs, which are manufactured in small plants in the United States, were manufactured in India without approval. There were numerous misunderstandings among manufacturers regarding the proper strategy for bringing generic medications to market, resolving data integrity issues, and the sales and marketing aspects of drugs for a successful outcome. In recent years, India has been subjected to increased inspections by international regulatory bodies. Regulatory bodies have taken a greater number of enforcement actions in cases involving data integrity. Based on the license, impact, and issues involved in this review, it was concluded that what are the current trends in generic drugs and their category, as well as the recommendations to be followed to avoid further issues in the future.